Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q2 2024 · 10-Q
Revenue$211.50M$211.50M+15.3% vs Q2 2023 Net Income-$36.70M-$36.70MN/M vs Q2 2023 EPS Diluted-$0.41-$0.41N/M vs Q2 2023 Gross Profit$147,100,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,600,000N/M Margins · derivedGross margin69.6%
Operating margin-17.3%+44.7 pt vs Q2 2023
Net margin-17.4%+45.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end